|
|
Volumn 374, Issue 26, 2016, Pages 2600-2601
|
|
The author replies
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY;
BELATACEPT;
CALCINEURIN INHIBITOR;
COMPLEMENT COMPONENT C4D;
CYCLOSPORIN;
MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR;
MYCOPHENOLATE MOFETIL;
TACROLIMUS;
ABATACEPT;
IMMUNOSUPPRESSIVE AGENT;
ACUTE GRAFT REJECTION;
ANTIBODY MEDIATED REJECTION;
ANTIBODY PRODUCTION;
ANTIBODY SPECIFICITY;
DELAYED GRAFT FUNCTION;
DRUG DOSE COMPARISON;
DRUG EFFICACY;
DRUG EXPOSURE;
DRUG SAFETY;
GLOMERULUS FILTRATION;
GLOMERULUS FILTRATION RATE;
GRAFT FAILURE;
GRAFT INFECTION;
HELPER CELL;
HUMAN;
HUMORAL IMMUNITY;
IMMUNOSUPPRESSIVE TREATMENT;
KIDNEY DONOR;
KIDNEY FUNCTION;
KIDNEY TRANSPLANTATION;
LETTER;
LYMPHOCYTE ACTIVATION;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
GRAFT SURVIVAL;
KIDNEY FAILURE, CHRONIC;
ABATACEPT;
CYCLOSPORINE;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
KIDNEY FAILURE, CHRONIC;
KIDNEY TRANSPLANTATION;
|
|
EID: 84976517789
PISSN: 00284793
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJMc1602859 Document Type: Letter |
|
Times cited : (68)
|
|
References (4)
|
